Literature DB >> 26268223

A PK-PD model of ketamine-induced high-frequency oscillations.

Francisco J Flores1, ShiNung Ching, Katharine Hartnack, Amanda B Fath, Patrick L Purdon, Matthew A Wilson, Emery N Brown.   

Abstract

OBJECTIVE: Ketamine is a widely used drug with clinical and research applications, and also known to be used as a recreational drug. Ketamine produces conspicuous changes in the electrocorticographic (ECoG) signals observed both in humans and rodents. In rodents, the intracranial ECoG displays a high-frequency oscillation (HFO) which power is modulated nonlinearly by ketamine dose. Despite the widespread use of ketamine there is no model description of the relationship between the pharmacokinetic-pharmacodynamics (PK-PDs) of ketamine and the observed HFO power. APPROACH: In the present study, we developed a PK-PD model based on estimated ketamine concentration, its known pharmacological actions, and observed ECoG effects. The main pharmacological action of ketamine is antagonism of the NMDA receptor (NMDAR), which in rodents is accompanied by an HFO observed in the ECoG. At high doses, however, ketamine also acts at non-NMDAR sites, produces loss of consciousness, and the transient disappearance of the HFO. We propose a two-compartment PK model that represents the concentration of ketamine, and a PD model based in opposing effects of the NMDAR and non-NMDAR actions on the HFO power. MAIN
RESULTS: We recorded ECoG from the cortex of rats after two doses of ketamine, and extracted the HFO power from the ECoG spectrograms. We fit the PK-PD model to the time course of the HFO power, and showed that the model reproduces the dose-dependent profile of the HFO power. The model provides good fits even in the presence of high variability in HFO power across animals. As expected, the model does not provide good fits to the HFO power after dosing the pure NMDAR antagonist MK-801. SIGNIFICANCE: Our study provides a simple model to relate the observed electrophysiological effects of ketamine to its actions at the molecular level at different concentrations. This will improve the study of ketamine and rodent models of schizophrenia to better understand the wide and divergent range of effects that ketamine has.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26268223      PMCID: PMC5764707          DOI: 10.1088/1741-2560/12/5/056006

Source DB:  PubMed          Journal:  J Neural Eng        ISSN: 1741-2552            Impact factor:   5.379


  46 in total

1.  The effect of dopamine receptor blockade in the rodent nucleus accumbens on local field potential oscillations and motor activity in response to ketamine.

Authors:  Pawel Matulewicz; Stefan Kasicki; Mark Jeremy Hunt
Journal:  Brain Res       Date:  2010-10-01       Impact factor: 3.252

2.  Disruption of prefrontal cortex large scale neuronal activity by different classes of psychotomimetic drugs.

Authors:  Jesse Wood; Yunbok Kim; Bita Moghaddam
Journal:  J Neurosci       Date:  2012-02-29       Impact factor: 6.167

3.  Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease.

Authors:  Peter Lockwood; Wayne Ewy; David Hermann; Nick Holford
Journal:  Pharm Res       Date:  2006-08-12       Impact factor: 4.200

4.  NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia.

Authors:  S Kapur; P Seeman
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

5.  Reduced sensitivity to ketamine and pentobarbital in mice lacking the N-methyl-D-aspartate receptor GluRepsilon1 subunit.

Authors:  Andrey B Petrenko; Tomohiro Yamakura; Naoshi Fujiwara; Ahmed R Askalany; Hiroshi Baba; Kenji Sakimura
Journal:  Anesth Analg       Date:  2004-10       Impact factor: 5.108

6.  Real-time closed-loop control in a rodent model of medically induced coma using burst suppression.

Authors:  ShiNung Ching; Max Y Liberman; Jessica J Chemali; M Brandon Westover; Jonathan D Kenny; Ken Solt; Patrick L Purdon; Emery N Brown
Journal:  Anesthesiology       Date:  2013-10       Impact factor: 7.892

7.  Pharmacodynamic modeling of the EEG effects of ketamine and its enantiomers in man.

Authors:  J Schüttler; D R Stanski; P F White; A J Trevor; Y Horai; D Verotta; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1987-06

8.  Antipsychotic compounds differentially modulate high-frequency oscillations in the rat nucleus accumbens: a comparison of first- and second-generation drugs.

Authors:  Maciej Olszewski; Joanna Piasecka; Sailaja A Goda; Stefan Kasicki; Mark J Hunt
Journal:  Int J Neuropsychopharmacol       Date:  2012-11-21       Impact factor: 5.176

9.  HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine.

Authors:  Xiangdong Chen; Shaofang Shu; Douglas A Bayliss
Journal:  J Neurosci       Date:  2009-01-21       Impact factor: 6.167

10.  Differential effects of NMDA antagonists on high frequency and gamma EEG oscillations in a neurodevelopmental model of schizophrenia.

Authors:  K G Phillips; M C Cotel; A P McCarthy; D M Edgar; M Tricklebank; M J O'Neill; M W Jones; K A Wafford
Journal:  Neuropharmacology       Date:  2011-04-19       Impact factor: 5.250

View more
  4 in total

1.  Suppression of Parvalbumin Interneuron Activity in the Prefrontal Cortex Recapitulates Features of Impaired Excitatory/Inhibitory Balance and Sensory Processing in Schizophrenia.

Authors:  Oana Toader; Moritz von Heimendahl; Niklas Schuelert; Wiebke Nissen; Holger Rosenbrock
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

2.  Network and synaptic mechanisms underlying high frequency oscillations in the rat and cat olfactory bulb under ketamine-xylazine anesthesia.

Authors:  Władysław Średniawa; Jacek Wróbel; Ewa Kublik; Daniel Krzysztof Wójcik; Miles Adrian Whittington; Mark Jeremy Hunt
Journal:  Sci Rep       Date:  2021-03-18       Impact factor: 4.379

3.  Electroencephalographic slow wave dynamics and loss of behavioural responsiveness induced by ketamine in human volunteers.

Authors:  Jamie Sleigh; Rebecca M Pullon; Phillip E Vlisides; Catherine E Warnaby
Journal:  Br J Anaesth       Date:  2019-09-03       Impact factor: 9.166

4.  Nasal respiration is necessary for ketamine-dependent high frequency network oscillations and behavioral hyperactivity in rats.

Authors:  Jacek Wróbel; Władysław Średniawa; Gabriela Jurkiewicz; Jarosław Żygierewicz; Daniel K Wójcik; Miles Adrian Whittington; Mark Jeremy Hunt
Journal:  Sci Rep       Date:  2020-11-04       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.